Cargando…

Newborn Screening for Fabry Disease: Current Status of Knowledge

Fabry disease is an X-linked progressive lysosomal disorder, due to α-galactosidase A deficiency. Patients with a classic phenotype usually present in childhood as a multisystemic disease. Patients presenting with the later onset subtypes have cardiac, renal and neurological involvements in adulthoo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gragnaniello, Vincenza, Burlina, Alessandro P., Commone, Anna, Gueraldi, Daniela, Puma, Andrea, Porcù, Elena, Stornaiuolo, Maria, Cazzorla, Chiara, Burlina, Alberto B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299185/ https://www.ncbi.nlm.nih.gov/pubmed/37367212 http://dx.doi.org/10.3390/ijns9020031

Ejemplares similares

Abnormal activation of MAPKs pathways and inhibition of autophagy in a group of patients with Zellweger spectrum disorders and X-linked adrenoleukodystrophy
por: Gragnaniello, Vincenza, et al.
Publicado: (2023)

Newborn Screening for Fabry Disease in Northeastern Italy: Results of Five Years of Experience
por: Gragnaniello, Vincenza, et al.
Publicado: (2021)

Newborn screening for Pompe disease in Italy: Long-term results and future challenges
por: Gragnaniello, Vincenza, et al.
Publicado: (2022)

Implementation of Second-Tier Tests in Newborn Screening for Lysosomal Disorders in North Eastern Italy
por: Burlina, Alberto B., et al.
Publicado: (2019)

Bone disease in early detected Gaucher Type I disease: A case report
por: Gragnaniello, Vincenza, et al.
Publicado: (2022)

Report of Five Years of Experience in Neonatal Screening for Mucopolysaccharidosis Type I and Review of the Literature
por: Gragnaniello, Vincenza, et al.
Publicado: (2020)

A new strategy of desensitization in mucopolysaccharidosis type II disease treated with idursulfase therapy: A case report and review of the literature
por: Gragnaniello, Vincenza, et al.
Publicado: (2022)

Unusual Evolution of Hypertrophic Cardiomyopathy in Non-Compaction Myocardium in a Pompe Disease Patient
por: Gragnaniello, Vincenza, et al.
Publicado: (2023)

The Impact of a Slow-Release Large Neutral Amino Acids Supplement on Treatment Adherence in Adult Patients with Phenylketonuria
por: Burlina, Alessandro P., et al.
Publicado: (2020)

Large Neutral Amino Acid Therapy Increases Tyrosine Levels in Adult Patients with Phenylketonuria: A Long-Term Study
por: Burlina, Alessandro P., et al.
Publicado: (2019)

Congenital hyperinsulinism in clinical practice: From biochemical pathophysiology to new monitoring techniques
por: Martino, Mariangela, et al.
Publicado: (2022)

Newborn screening in mucopolysaccharidoses
por: Donati, Maria Alice, et al.
Publicado: (2018)

Correction to: Newborn screening in mucopolysaccharidoses
por: Donati, Maria Alice, et al.
Publicado: (2019)

Neonatal Expanded Screening toward lysosomal storage disorders
por: Burlina, Alberto, et al.
Publicado: (2015)

Survey of Italian pediatricians’ perspectives and knowledge about neonatal screening
por: Burlina, Alberto B., et al.
Publicado: (2015)

Quality of Life (QoL) assessment in a cohort of patients with Phenylketonuria
por: Cazzorla, Chiara, et al.
Publicado: (2014)

Clinical experience with N-carbamylglutamate in a single-centre cohort of patients with propionic and methylmalonic aciduria
por: Burlina, Alberto, et al.
Publicado: (2016)

FAbry STabilization indEX (FASTEX): an innovative tool for the assessment of clinical stabilization in Fabry disease
por: Mignani, Renzo, et al.
Publicado: (2016)

Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy
por: Salviati, Alessandro, et al.
Publicado: (2010)

Expert opinion of an Italian working group on the assessment of cognitive, psychological, and neurological outcomes in pediatric, adolescent, and adult patients with phenylketonuria
por: Manti, Filippo, et al.
Publicado: (2022)

Correction: Expert opinion of an Italian working group on the assessment of cognitive, psychological, and neurological outcomes in pediatric, adolescent, and adult patients with phenylketonuria
por: Manti, Filippo, et al.
Publicado: (2023)

Health-related quality of life in a european sample of adults with early-treated classical PKU
por: Maissen-Abgottspon, Stephanie, et al.
Publicado: (2023)

Fabry disease and multiple sclerosis misdiagnosis: the role of family history and neurological signs
por: Colomba, Paolo, et al.
Publicado: (2018)

Genomic screening of Fabry disease in young stroke patients: the Taiwan experience and a review of the literature
por: Lee, T.‐H., et al.
Publicado: (2018)

Newborn screening for Fabry disease in the north-west of Spain
por: Colon, Cristobal, et al.
Publicado: (2017)

Newborn screening for Fabry disease in the western region of Japan
por: Sawada, Takaaki, et al.
Publicado: (2020)

Understanding the Pathogenesis of Cardiac Complications in Patients with Propionic Acidemia and Exploring Therapeutic Alternatives for Those Who Are Not Eligible or Are Waiting for Liver Transplantation
por: Maines, Evelina, et al.
Publicado: (2023)

Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment
por: Politei, Juan M., et al.
Publicado: (2016)

Italian national consensus statement on management and pharmacological treatment of phenylketonuria
por: Burlina, Alberto, et al.
Publicado: (2021)

Expanded Newborn Screening in Italy Using Tandem Mass Spectrometry: Two Years of National Experience
por: Ruoppolo, Margherita, et al.
Publicado: (2022)

Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel
por: Burlina, Alessandro P, et al.
Publicado: (2011)

Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study
por: Germain, Dominique P., et al.
Publicado: (2018)

A New Approach to Objectively Evaluate Inherited Metabolic Diseases for Inclusion on Newborn Screening Programmes
por: Burlina, Alberto, et al.
Publicado: (2022)

Application of a Novel Algorithm for Expanding Newborn Screening for Inherited Metabolic Disorders across Europe
por: Jones, Simon A., et al.
Publicado: (2022)

Immune responses to alglucosidase in infantile Pompe disease: recommendations from an Italian pediatric expert panel
por: Gragnaniello, Vincenza, et al.
Publicado: (2022)

Living with phenylketonuria in adulthood: The PKU ATTITUDE study
por: Cazzorla, Chiara, et al.
Publicado: (2018)

Apparent diffusion coefficient restriction in the white matter: going beyond acute brain territorial ischemia
por: Citton, Valentina, et al.
Publicado: (2011)

Newborn Screening: Current Status in Alberta, Canada
por: De Souza, Andy, et al.
Publicado: (2019)

Current Status of Newborn Screening in Southeastern Europe
por: Koracin, Vanesa, et al.
Publicado: (2021)

Institutions and the uneven geography of the first wave of the COVID‐19 pandemic
por: Rodríguez‐Pose, Andrés, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_amrchio69sth9qtuncicl3t4hj